

DRAFT/UNAPPROVED

**VIRGINIA BOARD OF PHARMACY  
MINUTES OF BOARD MEETING**

June 21, 2018  
Second Floor  
Board Room 2

Perimeter Center  
9960 Mayland Drive  
Henrico, Virginia 23233-1463

- CALL TO ORDER:** The meeting was called to order at 9:15am
- PRESIDING:** Jody H. Allen (until 9:40am)  
Ryan K. Logan, Chairman (arrived 9:40am)
- MEMBERS PRESENT:** Melvin L. Boone, Sr.  
Cheryl H. Nelson  
Sheila K. W. Elliott  
Rafael Saenz  
Cynthia Warriner
- MEMBERS ABSENT:** Rebecca Thornbury  
Michael I. Elliott  
James L. Jenkins, Jr.
- STAFF PRESENT:** Caroline D. Juran, Executive Director  
J. Samuel Johnson, Jr., Deputy Executive Director  
Ellen B. Shinaberry, Deputy Executive Director  
Beth O'Halloran, Deputy Executive Director (arrived 9:17am)  
David E. Brown, Director, DHP (departed 9:27am)  
Barbara Allyson-Bryan, Chief Deputy Director, DHP  
James Rutkowski, Assistant Attorney General
- QUORUM:** With six members present, a quorum was established.
- APPROVAL OF AGENDA:** An amended agenda was provided as a handout that included an additional item under New Business, "Consultation with legal counsel pursuant to §2.2-3711(A)(7). Additionally, staff requested verbally that an additional item be added under New Business regarding an ADA accommodation request.
- MOTION:** **The Board voted unanimously to approve the agenda as requested and amended. (motion by Warriner, second by Boone)**
- APPROVAL OF MINUTES:** A handout of the draft minutes for the June 5, 2018 special conference committee meeting was provided for adoption.
- MOTION:** **The Board voted unanimously to adopt the minutes as presented for the meetings held between March 28, 2018 and June 5, 2018. (motion by Saenz, second by S. Elliott)**
- PUBLIC COMMENTS:** Lauren Berton Paul, Senior Director of CVS, provided comment in

support of the petition for rulemaking regarding labeling requirements for alternate delivery. Ms. Paul stated the ISMP recommended best practice for white space on a label makes this requirement very difficult and that listing two pharmacy names on a label can be confusing to a patient. Ms. Paul stated that since the patients request to have the drug sent from a specialty pharmacy to a local pharmacy, they are aware of the two pharmacies involved in the process.

Christina Barrille, Executive Director for VPhA, expressed appreciation for the professionalism in implementing the pharmaceutical processor request for application, encouraged the board to support the choosing of local Virginia businesses in the review of the pharmaceutical processor applications, and encouraged physician and pharmacist training. Ms. Barrille also encourages the Board to urge the Administration to pass pending regulatory changes that have been pending for several years in some cases, e.g., the prohibition of incentives to transfer prescriptions and the allowance for a pharmacist to dispense a larger quantity of Schedule VI drugs, taking refills into consideration. She also stated VPhA members remain concerned with PBMs. She stated the Board should recognize that payment issues do create patient access concerns and that VPhA encourages the regulating of PBMs and increased transparency. Lastly, she provided a handout to the Board reflecting a VPhA member's comments on the pharmaceutical processors.

Ms. Juran shared a written comment from former board member Robbie Rhodes. He expressed concern raised by others at a recent VPhA law rally that the proposed requirement for a pharmacy to perform daily temperature checks should apply to nonresident pharmacies as well, particularly mail order pharmacies. He further shared concern for delivered drugs being ruined when left in mailboxes unchecked.

Ms. Juran shared a second written comment received that expressed concern for PBM practices and encouraged the Board to regulate the PBMs. She reported that she informed the commenter that the 2016 PBM workgroup concluded that legislative action would be needed, not regulatory action.

## DIRECTOR'S REPORT

Dr. Barbara Allyson-Bryan provided the director's report as Dr. Brown had to step out for another meeting. She reported that Dr. Hughes Melton was recently appointed as Director of the Department of Behavioral Health and Developmental Services. Dr. Marissa Levine, former Commissioner of the Department of Health has moved to Florida and the new Health Commissioner is Dr. Norman Oliver. Dr. Allyson-Bryan stated that a public comment period has opened on the regulations for the autonomous practice of nurse practitioners. She reported that community health workers will now need to certify or register, however, VDH is already registering these persons. This subject is under review. DHP has been asked to look at the implications of providing physicians with overdose information. DHP has also been asked to define conversion therapy for children. Lastly, she reported that the e-prescribing workgroup will be re-convened in August.

LEGISLATIVE/  
REGULATORY/GUIDANCE:

Regulatory Update

Ms. Juran stated that Ms. Yeatts could not be present for the meeting. Ms. Juran reviewed with the Board the chart of regulatory actions provided in the agenda packet. She noted the following updates since the posting of the agenda packet:

- The controlled substance registration for naloxone and teleprescribing action was signed on 6/15/18 and there will be a public hearing on 8/23/18 at 9:30am. The public comment period will be open from 7/9/18 through 9/7/18.
- The increase in fees action has moved on to the next stage as the Department of Planning and Budget completed its review on 6/15/18.

Adoption of Exempt Regulation  
to Add Certain Schedule  
Chemicals to Schedule I and  
Scheduling/De-scheduling to  
Conform to Federal Actions

There was a public hearing conducted at 9:10am this morning pursuant to requirements of §54.1-3443(D and E) of the Drug Control Act.

**MOTION:**

**The Board voted unanimously to adopt an exempt action amendment of Regulation 18VAC110-20-322 pursuant to §54.1-3443(D) as presented which strikes chemicals in subsections A-D since they have now been scheduled in law and places the following chemicals into Schedule I:**

**Classified as research chemical:**

- **2,5-dimethoxy-4-chloroamphetamine (other name: DOC)**

**Classified as a cannabimimetic agent:**

- **1-(4-cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-carboxamide (other name: 4-cyano CUMYL-BUTINACA)**

**Classified as powerful synthetic opioids:**

- **N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamine (other name: Ocfentanil)**
- **N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide (other name: 4-methoxybutyrylfentanyl)**
- **N-phenyl-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name: isobutyryl fentanyl)**
- **N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-cyclopentanecarboxamide (other name: Cyclopentyl fentanyl)**
- **N-phenyl-N-(1-methyl-4-piperidinyl)-propanamide (other name: N-methyl norfentanyl)**

**Classified as a benzodiazepine with no accepted use in the US:**

- **Flualprazolam.**

**The Board further adopted 18VAC110-20-323 pursuant to §54.1-3443(E) which conforms State scheduling to the following federal scheduling actions:**

- **Adds MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine) to Schedule I;**
- **Adds Dronabinol [(-)-delta-9-*trans* tetrahydrocannabinol] in an oral solution in a drug product approved for marketing by the U.S. Food and Drug Administration to Schedule II; and**
- **Removes naldemedine from Schedule II. (motion by Warriner, second by Boone)**

Report from Regulation  
Committee Meeting and Possible  
Action:

Review of Guidance Documents

Mr. Elliott, Chairman of the Regulation Committee, could not attend today's full board meeting, therefore, Ms. Juran reported the Regulation Committee's recommendations for re-adoption of Guidance Documents that had not been acted upon in several years. The committee requested staff to determine if Guidance Document 110-6 was in need of revisions. She reported that she conferred with Ralph Orr, Director of the PMP, and that staff recommends deletion of the guidance document as it has not been utilized in recent years and does not accurately reflect current processes. Ms. Juran reported that Rebecca Thornbury recommended the suggested edit for Guidance Document 110-16 as presented in the agenda packet. Staff recommended the deletion of Guidance Documents 110-13 and 110-14 as they represent Orders imposed in 1997 and are otherwise available as public information. Ms. Warriner shared with the Board that the Regulation Committee had thoroughly vetted the documents during its review process.

**MOTION:**

**The Board voted unanimously to re-adopt Guidance Documents 110-10, 110-11, 110-19, 110-22, 110-24, and 110-25 (motion by Warriner, second by Saenz)**

**The Board voted unanimously to delete Guidance Documents 110-6, 110-13, and 110-14. (motion by Boone, second by Warriner)**

**The Board voted unanimously to amend Guidance Document 110-16 as presented. (motion by Warriner, second by Boone)**

Petition for Rulemaking from  
Lavino/CVS Health regarding  
18VAC110-20-275

It was reported that the Regulation Committee voted 3:2 in favor of recommending to the full board that it initiate rulemaking in response to the petition received from Lavino/CVS Health.

**MOTION:**

**The Board voted 5:1 in favor of initiating rulemaking by publishing a Notice of Intended Regulatory Action in response to the petition received from Lavino/CVS Health. (motion Allen, second Saenz; Warriner opposed)**

Adoption of Revised Emergency  
Regulations for Pharmaceutical

Processors

Because of successful 2018 legislation, the emergency regulations for pharmaceutical processors need to be revised to conform the emergency regulations to the new changes in law. It was reported that the Regulation Committee reviewed the proposed changes and asked staff to research the number of plants required to provide a 90-day supply as referenced in 18VAC110-60-240(A)(1). Ms. Juran stated that staff recommends 12 plants based on past discussions during the Regulatory Advisory Panel meetings that developed the recommended regulations for board consideration. It was further stated that the Regulation Committee recommends adoption of the revised emergency regulations. Ms. Juran also reported that the Board will need to adopt permanent replacement regulations at the September 2018 full board meeting and that a 30-day public comment period will be opened prior to the meeting. Information regarding the public comment period will be posted as a General Notice on the Regulatory Town Hall website.

**MOTION:**

**The Board voted unanimously to adopt the revised emergency regulations for pharmaceutical processors as presented. (motion by Warriner, second by S. Elliott)**

Adoption of Emergency Regulations Related to Delivery of Schedule VI Devices

Ms. Juran stated that HB878 and SB413 requires the board to promulgate regulations related to the delivery of Schedule VI devices within 280 days of their enactment. She provided a general overview of the draft language provided in the agenda packet and stated that the interested stakeholders who requested introduction of the legislation were supportive of the draft language.

**MOTION:**

**The Board voted unanimously to adopt emergency regulations as drafted to become effective and filed on or after July 1, 2018 and to approve a Notice of Intended Regulatory Action to replace the emergency regulations. (motion by Saenz, second by Warriner)**

Adoption of Exempt Regulations for Nonresident Warehousemen and Nonresident Third Party Logistics Providers

HB 520 created two new licensing categories: nonresident warehousemen and nonresident third party logistics providers. The Board must amend regulations to reference the new licensing categories.

**MOTION:**

**The Board voted unanimously to amend sections of 18VAC110-50-10 et seq., as presented in the agenda packet. (motion by Warriner, second by Allen)**

Adoption of Fast Track Regulation to Rescind Pharmacy Permit if Not Operational

Ms. Juran stated that board staff has noted recently there have been several instances in which a pharmacy permit was obtained, yet the pharmacy, after one year, has never opened. There have also been instances in which the pharmacy opens, however, no drugs are stocked. It is feared there may be fraudulent activity occurring in some instances and the board does not have the ability to rescind a permit once it is issued. During the periodic regulatory review, the Board adopted a proposed amendment to allow the board to rescind a pharmacy permit if the

pharmacy has not become operational within 90 days, unless there is good cause for the delay. The Board understood that at times there may be delay due to extraordinary circumstances. During the discussion, Mr. Johnson and Ms. O'Halloran noted that a change of ownership was not included in the draft language and yet they are aware of concerns involving pharmacies that do not resume operation after performing a change of ownership. There was discussion regarding how staff would know when to rescind a permit and acknowledgement that the Bylaws (Guidance Document 110-12) may need to be amended, if the regulation becomes effective, to outline a process for the executive director to coordinate with the board chairman during the decision-making process.

**MOTION:**

**The Board voted unanimously to adopt the amendment of 18VAC110-20-140(F) as amended to read: "If the pharmacy is not fully operational within 90 days of issuance of a permit or change of ownership, the board may rescind such permit. For good cause shown, such as circumstances beyond the control of the permit holder, the board may grant an extension". (motion by Allen, second by S. Elliott)**

Mr. Logan, who had a flat tire this morning, arrived and began presiding over the meeting.

Report From the Ad Hoc  
Inspection Committee Meeting  
and Possible Action

Jody Allen, Chairman of the ad hoc committee that met on June 20, 2018, presented the committee's report. She stated that the inspection report was discussed at the committee meeting and suggested changes were reviewed. The committee also recommended the board adopt the amendments to Guidance Document 110-9 as presented in the handout, with the exception of one error in Deficiency #4 wherein "first citation" should read "documented occurrence".

**MOTION:**

**The Board voted unanimously to adopt the amendments to Guidance Document 110-9 as presented in the handout, with the exception of one error in Deficiency #4 wherein "first citation" should read "documented occurrence". (motion by Warriner, second by Boone)**

**OLD BUSINESS:**

Request from Gates Healthcare  
Associates, Inc. Regarding  
cGMP Inspections

Denise Frank, Senior Associate with Gates Healthcare Associates, Inc. provided brief comment regarding their request to have their cGMP inspection reports accepted for licensure purposes of an outsourcing facility, in lieu of an FDA inspection, when an FDA inspection has not been performed in a timely manner for the applicant to comply with Virginia law. Ms. Juran informed the board that additional information, as requested by the board at the last board meeting, was received by staff, but that Gates requested that the inspection-related information not be shared publically. Ms. Juran stated that the law did not allow the board to review the information confidentially without sharing with the public. Ms. Frank indicated that she just sent via email a revised version that

could be shared with the board and public. Several questions were asked of Ms. Frank. She stated there is currently one trained inspector of cGMPs who formerly worked with the FDA, but that other inspectors could be trained as necessary. She stated that Gates is not currently performing cGMP inspections for any other states, but that Gates is currently engaged in conversations with several states and that Gates has assisted some facilities in responding to FDA observations. She also reported that there is no defined inspection report to share currently such as a checklist that boards are familiar with using in routine pharmacy inspections, but that Gates could develop such and reflect whatever information the Board desires.

Mr. Logan recommended and the Board agreed to defer the request to a later meeting for consideration after reviewing the additional information Ms. Frank has emailed to staff.

**NEW BUSINESS:**

Presentation of 2017 Pharmacist  
and Pharmacy Technician  
Workforce Reports

Dr. Elizabeth A. Carter, Director of DHP Healthcare Workforce Data Center, provided a summary presentation of the work the center has done in collecting and presenting the reports of pharmacist and pharmacy technician workforce. There was a 96-98% response rate during the 2017 survey. When providing a general overview of the reports, she noted that 56% of the licensees have a relationship with Virginia, either having been born in Virginia, currently residing in Virginia, or having attended school in Virginia. This is higher than other professions. Pharmacy technicians have a higher percentage rate from rural backgrounds. Dr. Carter also demonstrated the new interactive Virginia CareForce Snapshots and Regional CareForce Snapshots, along with the Trends in Healthcare Workforce Full Time Equivalency Units report available at [www.dhp.virginia.gov/hwdc](http://www.dhp.virginia.gov/hwdc). Additionally, she provided a handout representing the overall breakout of individual disease states selected by responders for the newly added survey question regarding collaborative practice agreements. Results indicate 30% of the survey respondents reported participating in a collaborative practice agreement for diabetes, 23% participate in hypercholesterolemia, 25% participate in hypertension, 15% participate in tobacco cessation, and 7% participate in travel medications. She also provided handouts regarding pharmacist and pharmacy technician labor market information from [www.virginiaLMI.com](http://www.virginiaLMI.com). The Board thanked Dr. Carter for the very informative report.

**MOTION:**

**The Board voted unanimously to adopt the 2017 workforce data reports for pharmacists and pharmacy technicians. (motion by Warriner, second by Saenz)**

Consideration for a Board  
Retreat

Ms. Juran asked if the Board would be interested in having a one-day retreat this fall, perhaps in October, that would allow the members and staff to receive education on topics such as production and use of CBD/THC-A oil, pharmaceutical processor oversight, current trends to move toward a standard of care approach in regulatory oversight, and

advances in pharmacy technology and security systems. Ms. Juran noted that the Governor will potentially appoint 5-6 new board members prior to the September board meeting. The education may assist the Board in future regulatory and enforcement actions. There was general support expressed by the Board for this retreat.

Elections for Chairman and Vice-Chairman

**MOTION:** **The board voted unanimously to elect Rafael Saenz as Chairman of the Board for the term July 1, 2018 through June 30, 2019. (motion by Boone, second by Warriner)**

**MOTION:** **The board voted unanimously to elect Cindy Warriner as Vice Chairman of the Board for the term July 1, 2018 through June 30, 2019. (motion by Allen, second by Boone)**

The Board decided to consider the ADA accommodation request after all reports were received since the request would require the Board to enter into a closed session.

Chairman's Report

Mr. Logan provided information on the NABP meeting held in May in Denver, Colorado where he served as the elected delegate for the Resolutions Committee representing District 2 and the voting delegate for the Virginia Board. Mr. Logan encouraged everyone to attend this national meeting as he finds the information provided very valuable. He expressed appreciation for the opportunity to serve as the Board Chairman during the past year.

Report on Board of Health Professions

Mr. Logan reported that the next Board of Health Professions meeting is scheduled for June 26, 2018.

Report on Licensure Program

Mr. Johnson reported the Board currently licenses 36,648 individuals and facilities. The Board issued 912 licenses and registrations for the period of March 1, 2018 through May 31, 2018. Inspectors conducted 535 facility inspections including 218 routine inspections of pharmacies: 66 (30%) resulted in no deficiency, 80 (37%) with deficiencies and 72 (33%) with deficiencies and a consent order. Beginning with the September board meeting, the report of inspections and deficiencies will be modified to capture the impact of the amendments the Board approved to Guidance Document 110-9.

Report on Disciplinary Program

Ms. Shinaberry stated that as of 6/7/18 there were 296 open pharmacy cases. There has been an increase in cases recently primarily due to the CE audit. The board has six possible summary suspension cases it is working. She reported that the Board has worked through most of the older cases and currently has only three probable cause cases exceeding 250 days.

Executive Director's Report

Ms. Juran provided comment on the report provided in the agenda packet.



As noted earlier in the morning, she welcomed Cheryl Nelson as a newly appointed board member who is filling the unexpired term, previously held by Ms. Shinaberry that is set to expire June 30, 2018. She reported that Mr. Jenkins could not attend this first board meeting due to an already scheduled vacation. She provided an update on the pharmaceutical processor Request for Application, the deadline of which was 2pm on June 8, 2018. She reported that 53 applications were received. Four were deemed incomplete. Of those four, two were later deemed complete after review by the Office of the Attorney General. Of those 51 complete application, 9 applications were received in health service area I, 8 were received in health service area II, 10 were received in health service area III, 9 were received in health service area IV, and 15 were received in health service area V. The 51 complete applications will be evaluated by the ad hoc committee appointed by the Board Chairman. The ad hoc committee will tentatively meet in-person on July 30 and 31, 2018. Ms. Juran additionally noted that Ms. Shinaberry provided an excellent presentation at the NABP annual meeting regarding use of PMP data in regulating. Lastly, she stated Ralph Orr asked that she inform the Board that SB226, effective July 1, 2018, requires a pharmacy dispensing a covered substance for an animal to report the dispensing to the PMP using the animal owner's name and date of birth. A reporting exemption exists in §54.1-2522 for veterinarians dispensing a course of treatment not to last longer than 7 days. Ms. Juran stated that it is important that veterinarians issue prescriptions in accordance with the longstanding requirement of §54.1-3409 that requires the prescription to bear the full name of the owner of the animal and to include the species of the animal. Equally important, pharmacists must label and dispense the drug in compliance with the longstanding requirement of §54.1-3410 which requires the label to bear the name of the owner of the animal and the species of the animal. Ms. Juran reported that if the information reported to the PMP does not accurately reflect the owner's name, e.g., it's reported in the name of the animal, then the information in the database will not appropriately align with the name of the owner and the effort loses value.

**ACTION ITEM:**

**The Board requested that staff collaborate with the Board Chairman to draft an email to send to pharmacists and pharmacy technicians regarding suggestions for complying with the new PMP reporting requirement and reducing medication errors resulting from possible confusion between dispensed drugs intended for animals and owners. Guidance may include suggestions for pharmacies to use different caps on vials to distinguish between drugs intended for the animal verses the owner, use of auxiliary labels, or placing the animal's name in the directions field on the label to distinguish between multiple animals' drugs belonging to a single owner.**

Consultation with Legal Counsel  
Pursuant to §2.2-3711(A)(7)

**Motion for Closed Meeting:**

**Upon a motion by Jody Allen, and duly seconded by Cindy Warriner, the Board voted unanimously to convene a closed meeting pursuant**

to § 2.2-3711(A)(7) of the Code of Virginia (“Code”), for the purpose of consulting with legal counsel pertaining to actual or probable litigation, where such consultation or briefing in open meeting would adversely affect the negotiating or litigating posture of the public body. Additionally, she moved that Caroline Juran, Sammy Johnson, Beth O’Halloran, Ellen Shinaberry and Jim Rutkowski attend the closed meeting.

**Motion to Certify the Purpose of the Closed Session:**

Having certified that the matters discussed in the preceding closed meeting met the requirements of § 2.2-3712 of the Code, the Board re-convened an open meeting.

Consideration for ADA  
Accommodation Request on  
Licensure Examinations

**Motion for Closed Meeting:**

Upon a motion by Jody Allen, and duly seconded by Cindy Warriner, the Board voted unanimously to convene a closed meeting pursuant to § 2.2-3711(A)(16) of the Code of Virginia (“Code”), for the purpose of deliberation on the confidential handout to reach a decision regarding a request for an ADA accommodation for licensure examinations. Additionally, she moved that Caroline Juran, Sammy Johnson, Beth O’Halloran, Ellen Shinaberry and Jim Rutkowski attend the closed meeting.

**Motion to Certify the Purpose of the Closed Session:**

Having certified that the matters discussed in the preceding closed meeting met the requirements of § 2.2-3712 of the Code, the Board re-convened an open meeting and announced the decision.

**Decision:**

The Board approved the applicant’s request to extend the allotted amount of time for completing the MPJE and NAPLEX to an amount equal to double the normally allotted amount of time. (motion S. Elliott, second by Warriner)

Consideration of Summary  
Suspensions

Lindsey N. Brooks  
Registration No.: 0230-022588

Julia Bennett, Assistant Attorney General, presented a summary of the evidence in the case for the Board to consider a possible summary suspension. Mykl Egan, Adjudication Specialist, was also present.

**MOTION:**

Upon a motion by Jody Allen, and duly seconded by Cindy Warriner, the Board voted unanimously in favor of the motion that according to the evidence presented, the continued practice by Lindsey N. Brooks as a pharmacy technician poses a substantial danger to the public; and therefore, the registration for Ms. Brooks shall be summarily suspended. Further, in lieu of a formal hearing, a Consent Order shall be offered to Ms. Brooks for the indefinite suspension of her

**pharmacy technician registration for not less than two years.**

Tammy Lea Thompson  
Registration No.: 0230-002189

Wayne Halbleib, Senior Assistant Attorney General, presented a summary of the evidence in the case for the Board to consider a possible summary suspension. Mykl Egan, Adjudication Specialist, was also present.

**MOTION:**

**Upon a motion by Cindy Warriner, and duly seconded by Sheila Elliott, the Board voted unanimously in favor of the motion that according to the evidence presented, the continued practice by Tammy Lea Thompson as a pharmacy technician poses a substantial danger to the public; and therefore, the registration for Ms. Thompson shall be summarily suspended. Further, in lieu of a formal hearing, a Consent Order shall be offered to Ms. Thompson for the indefinite suspension of her pharmacy technician registration for not less than two years.**

John Daniel Barnett  
License No.: 0202-009362

James Schleissmann, Senior Assistant Attorney General, presented a summary of the evidence in the case for the Board to consider a possible summary suspension. Mykl Egan, Adjudication Specialist, was also present.

**MOTION:**

**Upon a motion by Sheila Elliott, and duly seconded by Melvin Boone, the Board voted unanimously in favor of the motion that according to the evidence presented, the continued practice by John Daniel Barnett as a pharmacist poses a substantial danger to the public; and therefore, the license for Mr. Barnett shall be summarily suspended. Further, in lieu of a formal hearing, a Consent Order shall be offered to Mr. Barnett for the indefinite suspension of his pharmacist license for not less than two years.**

Consideration of Consent Orders  
for Reinstatement

**MOTION FOR CLOSED  
MEETING:**

**Upon a motion by Jody Allen, and duly seconded by Cindy Warriner, the Board voted unanimously to convene a closed meeting pursuant to § 2.2-3711(A)(27) of the Code of Virginia (“Code”), for the purpose of presentation of evidence from Ellen Shinaberry, Deputy Executive Director, for consideration of three Consent Orders. Additionally, she moved that Caroline Juran, Ellen Shinaberry, and Jim Rutkowski attend the closed meeting.**

**Motion to certify the purpose  
of the closed meeting:**

**Having certified that the matters discussed in the preceding closed meeting met the requirements of § 2.2-3712 of the Code, the Board re-convened an open meeting and announced the decision.**

**DECISION:**

**Upon a motion by Cindy Warriner, and duly seconded by Jody Allen, the Board voted unanimously to accept the Consent Orders for:**

- **reinstatement of the nonresident medical equipment supplier**

**registration issued to Dependable Diabetic Supply, LLC  
(License No.: 0237000166);**

- **reinstatement of the nonresident medical equipment supplier registration issued to US Healthcare, LLC (License No.: 0237000216);**
- **temporary voluntary suspension of Angela D. Dillard's registration to practice as a pharmacy technician (Registration No: 0230-007092).**

ADJOURN:

With all business concluded, the meeting adjourned at approximately 2:48pm.

\_\_\_\_\_  
Ryan K. Logan, Chairman

\_\_\_\_\_  
Caroline D. Juran, Executive Director

\_\_\_\_\_  
DATE:

\_\_\_\_\_  
DATE: